Literature DB >> 1208760

Effects of diazepam and scopolamine on storage, retrieval and organizational processes in memory.

M M Ghoneim, S P Mewaldt.   

Abstract

The effects of intramuscular injections of diazepam (0.3 mg/kg) and scopolamine (8 mug/kg) on memory processes and subjective moods were studied in 36 volunteers. Subjects (Ss) were tested in groups of four in a double blind procedure with treatments distributed according to a Latin square design. Lists of words were presented to Ss who were then tested with an immediate free recall test prior to drug administration. Following injection delayed free recall and recognition tests were given. Subsequently two sets of lists were presented separately and tested in the same fashion. Two of the lists in the last set were composed of words falling into distinct categories. Memory was additionally analyzed by testing immediate recall of digit sequences and employing a visual recognition test. Subjective moods were evaluated with a rating questionnaire. Both diazepam and scopolamine impaired memory functions although the action of the latter drug was more pronounced and prolonged. The deficit appeared to be in the storage process leaving retrieval processes unaffected. Scopolamine in addition interfered with organizational processes. Subjectively, scopolamine also produced a larger sedative effect than diazepam.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1208760     DOI: 10.1007/bf00428903

Source DB:  PubMed          Journal:  Psychopharmacologia


  82 in total

1.  Functional MRI detection of pharmacologically induced memory impairment.

Authors:  Reisa Sperling; Douglas Greve; Anders Dale; Ronald Killiany; Jennifer Holmes; H Diana Rosas; Andrew Cocchiarella; Paul Firth; Bruce Rosen; Stephen Lake; Nicholas Lange; Carol Routledge; Marilyn Albert
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-26       Impact factor: 11.205

2.  Simulations of the role of the muscarinic-activated calcium-sensitive nonspecific cation current INCM in entorhinal neuronal activity during delayed matching tasks.

Authors:  Erik Fransen; Angel A Alonso; Michael E Hasselmo
Journal:  J Neurosci       Date:  2002-02-01       Impact factor: 6.167

3.  An inverse agonist selective for alpha5 subunit-containing GABAA receptors improves encoding and recall but not consolidation in the Morris water maze.

Authors:  N Collinson; J R Atack; P Laughton; G R Dawson; D N Stephens
Journal:  Psychopharmacology (Berl)       Date:  2006-04-22       Impact factor: 4.530

4.  Involvement of GABAergic systems in benzodiazepine-induced impairment of passive avoidance learning in mice.

Authors:  K Tohyama; T Nabeshima; K Ichihara; T Kameyama
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

5.  Dissociation of benzodiazepine-induced amnesia from sedation by flumazenil pretreatment.

Authors:  D Hommer; H Weingartner; A Breier
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

6.  Pharmacological models of memory dysfunction? A comparison of the effects of scopolamine and lorazepam on word valence ratings, priming and recall.

Authors:  F Schifano; H V Curran
Journal:  Psychopharmacology (Berl)       Date:  1994-07       Impact factor: 4.530

7.  A comparison of the effect of lorazepam on memory in heavy and low social drinkers.

Authors:  J M Nichols; F Martin; K C Kirkby
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

8.  Central effects in man of the novel schistosomicidal benzodiazepine meclonazepam.

Authors:  C O'Boyle; R Lambe; A Darragh
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

9.  Anxiolytic drugs and the acquisition of conditioned fear in mice.

Authors:  D J Sanger; D Joly
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

10.  Diazepam and memory: retrograde facilitation produced by interference reduction.

Authors:  J V Hinrichs; M M Ghoneim; S P Mewaldt
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.